Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2021
MindMed and Sphere Health announce research collaboration
MindMed and Sphere Health announced a collaboration to collect and analyze multimodal data through study MM061302, with the aim of improving understanding of biomarkers associated with mental illnesses.
2021
MindMed and Nextage announce collaborative development program
MindMed and Nextage Therapeutics announced an MOU for an exclusive collaborative development program to optimize delivery of certain psychedelic drug candidates using Nextage's Brain Targeting Liposome System. They said they would initially work on noribogaine-based drug products and share development costs and resulting intellectual property.
2021
MindMed appoints Peter Mack as VP of Pharmaceutical Development
MindMed appointed Peter Mack as Vice President of Pharmaceutical Development. He will lead product development activities across its investigational drug portfolio.
2021
MindMed begins trading on Nasdaq
MindMed began trading on the Nasdaq Capital Market under the symbol MNMD on April 27, 2021, while retaining its listing on the Neo Exchange.
2021
MindMed reports 2020 year-end financial results
Mind Medicine (MindMed) announced its annual 2020 financial results, including a net and comprehensive loss of $35.1 million and net cash used in operating activities of $24.2 million for the year ended December 31, 2020.
2021
MindMed closes CAD $92.1 million offering
Mind Medicine (MindMed) Inc. closed its bought-deal offering, issuing 20,930,000 units at CAD $4.40 per unit for gross proceeds of approximately CAD $92.1 million.
2020
MindMed funds psychedelic medicine research training program with NYU Langone
MindMed announced a $5 million commitment over five years to fund the NYU Langone Health Psychedelic Medicine Research Training Program and the future corresponding Center for Psychedelic Medicine. The program's launch was announced, while establishment of the Center remains subject to additional funding.
2020
MindMed signs exclusive LSD research collaboration and license
MindMed announced a multi-year exclusive collaboration with Professor Matthias Liechti's laboratory at University Hospital Basel, gaining exclusive worldwide rights to data, compounds, and patent rights associated with the laboratory's research on LSD and other psychedelic compounds.